Amyloid PET in neurodegenerative diseases with dementia

Data de publicació: 01/11/2018

Autors de IIS La Fe

Pablo Sopena Novales

Autor

Autors aliens a IIS La Fe

Camacho, V
Gomez-Grande, A
Garcia-Solis, D
Gomez Rio M
Lorenzo, C
Rubi, S
Arbizu, J
Grupo de Neuroimagen SEMNIM

Grups d'Investigació

Núcleo de investigación traslacional integrado Urológico de Valencia (NITIUV)

Leader

César David Vera Donoso

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased A beta(1-42) and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on F-18-FDG PET and temporal atrophy on MRI). Recently specific recommendations have been created as a consensus statement on the appropriate use of the imaging biomarkers, including amyloid PET: early-onset cognitive impairment/dementia, atypical forms of AD, mild cognitive impairment with early age of onset, and to differentiate between AD and other neurodegenerative diseases that occur with dementia. Amyloid PET is also contributing to the development of new therapies for AD, as well as in research studies for the study of other neurodegenerative diseases that occur with dementia where the deposition of A beta amyloid is involved in its pathogenesis. In this paper, we review some general concepts and study the use of amyloid PET in depth and its relationship with neurodegenerative diseases and other diagnostic techniques. (C) 2018 Sociedad Espanola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espana, S.L.U. All rights reserved.

Dades de la publicació

ISSN/ISSNe:: 2253-654X, 2253-8070
Tipus:: Article
Pàgines:: 397-406
DOI:: 10.1016/j.remn.2018.03.004
PubMed:: 29776894
Factor d'Impacte:: 0,235 SCImago ℠
Quartil:: Q3 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Camacho, V:: Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Espana

Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Serv Med Nucl, Barcelona, Spain
Gomez-Grande, A:: Servicio de Medicina Nuclear, Hospital 12 de Octubre, Madrid, Espana

Hosp 12 Octubre, Serv Med Nucl, Madrid, Spain
Sopena, P:: Servicio de Medicina Nuclear, Hospital Vithas-Nisa 9 de Octubre, Valencia, Espana

Servicio de Medicina Nuclear, Hospital Universitario y Politecnico la Fe, Valencia, Espana

Hosp Vithas Nisa 9 Octubre, Serv Med Nucl, Valencia, Spain

Hosp Univ & Politecn Fe, Serv Med Nucl, Valencia, Spain
Garcia-Solis, D:: Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocio, Sevilla, Espana

Hosp Univ Virgen del Rocio, Serv Med Nucl, Seville, Spain
Gomez Rio M:: Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Instituto de Investigacion Biosanitaria de Granada (IBS), Granada, Espana
Lorenzo, C:: Servicio de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Espana

Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Med Nucl, Barcelona, Spain
Rubi, S:: Servicio de Medicina Nuclear, Hospital Universitari Son Espases, Institut d'Investigacio Sanitaria Illes Balears (IdISBa), Palma, Espana

Hosp Univ Son Espases, Inst Invest Sanitaria Illes Balears IdISBa, Serv Med Nucl, Palma De Mallorca, Spain
Arbizu, J:: Servicio de Medicina Nuclear, Clinica Universidad de Navarra, Pamplona, Navarra, Espana

Clin Univ Navarra, Serv Med Nucl, Navarra, Spain
Grupo de Neuroimagen SEMNIM:: Grp Neuroimagen SEMNIM